NCT06799845 - Study Assessing Pain Relief After Replacement of the Knee | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

February 3, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Total Knee Arthroplasty (Postoperative Pain)

Interventions

DRUG

ATX101

ATX101 bupivacaine implants, total of 1,500 mg into the surgical site

DRUG

bupivacaine hydrochloride

bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration

DRUG

saline placebo

normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration

Trial Locations (11)

Chesapeake Research Group, LLC, Pasadena

Atlanta Centre for Medical Research, Atlanta

Phoenix Clinical Research, Tamarac

NextStage Clinical Research, Wichita

Woodland International Research Group, LLC, Little Rock

Legent Orthopedic Hospital, Carrollton

Memorial Hermann Village, Houston

First Surgical Hospital, Bellaire

Endeavor Clinical Trials, LLC, San Antonio

NextStage Clinical Research, San Antonio

JBR Clinical Research, LLC, Salt Lake City